We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Comparison of Three Chemotherapy Protocols With Electrochemotherapy for the Treatment of Feline Cutaneous Squamous Cell Carcinoma.
- Authors
Diop, Nicolas; Sayag, David; Marques, Grégoire Bernardo; Chamel, Gabriel; Chavalle, Thomas; Eon, Jean‐Bapiste; Floch, Franck; Lajoinie, Mathilde; Ponce, Frédérique; Barrett, Laura E.
- Abstract
Electrochemotherapy (ECT) with intravenous (IV) and/or intratumoral (IT) bleomycin has shown considerable efficacy in the treatment of non‐resectable feline cutaneous squamous cell carcinoma (cSCC), boasting response rates of up to 95%, but other chemotherapy protocols have not yet been investigated. The objective of this prospective multicentre study was to compare the overall response rate (ORR) and progression‐free interval (PFI) between cats with cSCC treated with ECT using IT and IV carboplatin (IV + IT), IV carboplatin (IV) or IV bleomycin (IV). A total of 44 cats with unresectable cSCC across three centres were enrolled and treated with ECT using carboplatin IV + IT (n = 10), carboplatin IV (n = 11) or bleomycin IV (n = 23). Treatment response according to RECIST criteria was recorded at 2 and 4 weeks post‐treatment, and patients were followed until disease progression and/or death. All three groups were comparable regarding age, sex, weight, and lesion size. Adverse events were generally mild, localised and similar between groups. ORRs were 90.0% (carboplatin IV + IT), 90.9% (carboplatin IV) and 95.6% (bleomycin IV) and were not significantly different (p = 0.79). Median PFI was not reached for carboplatin IV + IT or carboplatin IV and was 566 days for bleomycin IV, with no significant difference between the three groups (p = 0.81). This study suggests that ECT using IV or IV + IT carboplatin is a reasonable alternative therapeutic option for managing cSCC, and further studies are warranted to compare outcomes between treatment protocols.
- Subjects
SQUAMOUS cell carcinoma; BLEOMYCIN; CARBOPLATIN; MEDICAL protocols; DISEASE progression; CANCER chemotherapy
- Publication
Veterinary & Comparative Oncology, 2024, Vol 22, Issue 3, p437
- ISSN
1476-5810
- Publication type
Article
- DOI
10.1111/vco.12995